CARDIFF ONCOLOGY, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
CARDIFF ONCOLOGY, INC. (CRDF) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $269.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $135.00K, a 0.00% change year-over-year.
- CARDIFF ONCOLOGY, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $134.00K, a 0.74% decline year-over-year.
- CARDIFF ONCOLOGY, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $135.00K, a 0.00% change year-over-year.
- CARDIFF ONCOLOGY, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $135.00K, a 0.00% change year-over-year.
- CARDIFF ONCOLOGY, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $540.00K, a 0.19% increase from fiscal 2024.
- CARDIFF ONCOLOGY, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $539.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $269.00K 10-Q · filed 2026-08-11 | $404.00K derived: sum of 3 quarters · filed 2026-08-11 | $539.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $134.00K 10-Q · filed 2026-05-14 | $269.00K derived: sum of 2 quarters · filed 2026-05-14 | $404.00K derived: sum of 3 quarters · filed 2026-05-14 | $539.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $270.00K derived: sum of 2 quarters · filed 2026-02-24 | $405.00K derived: sum of 3 quarters · filed 2026-08-11 | $540.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $270.00K derived: sum of 2 quarters · filed 2026-08-11 | $405.00K 10-Q · filed 2025-11-06 | $540.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $270.00K 10-Q · filed 2026-08-11 | $405.00K derived: sum of 3 quarters · filed 2026-08-11 | $540.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $135.00K 10-Q · filed 2026-05-14 | $270.00K derived: sum of 2 quarters · filed 2026-05-14 | $405.00K derived: sum of 3 quarters · filed 2026-05-14 | $540.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $270.00K derived: sum of 2 quarters · filed 2026-02-24 | $405.00K derived: sum of 3 quarters · filed 2026-02-24 | $539.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $270.00K derived: sum of 2 quarters · filed 2025-11-06 | $404.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $269.00K 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $134.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |